Skip to main content
Premium Trial:

Request an Annual Quote

Quest Licenses HIV Tropism Assay from Pathway Diagnostics

NEW YORK (GenomeWeb News) — Quest Diagnostics has licensed from Pathway Diagnostics the underlying technology used in its co-receptor tropism HIV assay, Quest said today.
 
The non-exclusive license covers the heteroduplex tracking technology used in Pathway’s SensiTrop test. Quest said that a molecular-based assay for co-receptor tropism will help physicians personalize HIV therapy.
 
Quest, which is the first full-service national clinical laboratory in the US to license the technology, expects to develop a validated assay using the technology in the first quarter of 2008. Until then, the SensiTrop test may be ordered through Quest, which will refer the test to Pathway Diagnostics.
 
"HIV co-receptor tropism tests can help physicians identify which patients, of the estimated 500,000 people in the US being treated for HIV infection, will benefit from entry inhibitor drugs, the latest development in life-enhancing anti-retroviral therapies,” Joyce Schwartz, Quest’s vice president and chief laboratory officer, said in a statement.
 
Financial terms of the agreement were not released.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.